Drugs / ARO-HBV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03365947 | Mar 2018 → Apr 2020 | hepatitis B virus infection | Arrowhead Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2020-08-28 | Arrowhead Pharmaceuticals | Results Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress arrowheadpharma.com ↗
For the first time in patients with CHB, siRNA therapy resulted in sustained, off-treatment ≥1log10 IU/mL reductions in HBsAg through to 48 weeks in 39% of patients after the last JNJ-3989 dose |
| 2019-11-08 | Arrowhead Pharmaceuticals | Results Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019 arrowheadpharma.com ↗
The data is being presented in two poster presentations at The Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD). |
| 2019-04-12 | Arrowhead Pharmaceuticals | Results Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™ arrowheadpharma.com ↗
100% of patients (40 of 40) achieved ≥1.0 Log10 IU/mL HBsAg reduction |
| 2018-11-09 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018 arrowheadpharma.com ↗
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced preliminary clinical data from a Phase 1/2 study (AROHBV1001) of ARO-HBV, a third-generation subcutaneously administered RNA interference (RNAi) therapeutic candidate being developed as a potential treatment for patients with chronic hepatitis B virus (HBV) infection. |
| 2018-09-06 | Arrowhead Pharmaceuticals | Results Arrowhead Presents New ARO-HBV Clinical Data Demonstrating HBsAg Reductions at World Gastroenterologists Summit arrowheadpharma.com ↗
The data demonstrate that three monthly doses of ARO-HBV led to a maximum reduction in circulating HBV surface antigen (HBsAg) of 4.0 log10, with mean reductions of approximately 2.0 log10 on day 85 in the 100 mg cohort and 1.4 log10 on day 71 in the 200mg cohort (currently the last complete data point available). |
| 2018-02-15 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B arrowheadpharma.com ↗ |
| 2017-12-22 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV arrowheadpharma.com ↗
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it filed a regulatory submission to begin a Phase 1/2 study of ARO-HBV, which is being developed as a potentially curative therapy for patients with chronic hepatitis B virus (HBV) infection. |
| 2017-09-14 | Arrowhead Pharmaceuticals | Results Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM™ Platform and Lead RNAi-based Drug Candidates arrowheadpharma.com ↗
ARO-HBV, Arrowhead's third generation subcutaneously administered clinical candidate for the treatment of chronic hepatitis B virus infection, achieved up to 99.9% knockdown of hepatitis B surface antigen (HBsAg), e-antigen (HBeAg), and HBV DNA in rodent models. |
All press releases naming this drug 12 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARO-HBV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03365947 ↗ |